[1]赵海娟 李珂 赵耀 黄松群 郭志福.房颤导管消融术的创新和策略转变[J].心血管病学进展,2023,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.001]
　ZHAO Haijuan,LI Ke,ZHAO Yao,et al.Innovations and Paradigm Shifts In Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2023,(6):481.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.001]
点击复制

房颤导管消融术的创新和策略转变()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年6期
页码:
481
栏目:
综述
出版日期:
2023-06-25

文章信息/Info

Title:
Innovations and Paradigm Shifts In Atrial Fibrillation Ablation
作者:
赵海娟 李珂 赵耀 黄松群 郭志福
(海军军医大学第一附属医院心血管内科,上海 200433)
Author(s):
ZHAO Haijuan; LI Ke; ZHAO Yao; HUANG Songqun; GUO Zhifu
(Department of Cardiology,The First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)
关键词:
房颤; 肺静脉隔离; 导管消融; 房颤复发
Keywords:
Atrial fibrillation; Pulmonary vein isolation; Catheter ablation; Atrial fibrillation recurrence
DOI:
10.16806/j.cnki.issn.1004-3934.2023.06.001
摘要:
房颤的治疗在过去几十年中发生了巨大的变化，尤其是在非药物治疗方面取得了重要进展，导管消融术正逐步成为房颤患者的一线治疗方案。肺静脉隔离是导管消融的基石，但由于肺静脉隔离不完全和其他非肺静脉触发灶等因素，通常需再次行导管消融术，因此还需进一步开发消融设备，改进消融策略。现概述房颤导管消融术的发展，介绍最新技术以及临床研究和未来发展方向。
Abstract:
Treatment of atrial fibrillation has seen dramatic breakthroughs in the past decades ,especially in the field of non-pharmacological treatment. In order to have a better rhythm control,catheter ablation has gradually become the first-line therapy for patients with atrial fibrillation. Pulmonary vein isolation is the cornerstone of catheter ablation. However,re-do procedures are often necessary due to incomplete pulmonary vein isolation and non-pulmonary vein triggers. Therefore,there is further need for developing ablation tools and strategies that reproducibly isolate the pulmonary vein transmurally. In this review ,we will summarize the development of catheter ablation in atrial fibrillation,and introduce the latest technologies,clinical researches and future endeavours.

参考文献/References:

[1] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS):The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.

[2] Kuck KH,Brugada J,Fürnkranz A,et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation[J]. N Engl J Med,2016,374(23):2235-2245.

[3] Kuck KH,Hoffmann BA,Ernst S,et al. Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation:results from the Gap-atrial fibrillation-German atrial fibrillation competence network 1 trial[J]. Circ Arrhythm Electrophysiol,2016,9(1):e003337.

[4] Wyse DG,van Gelder IC,Ellinor PT,et al. Lone atrial fibrillation:does it exist?[J]. J Am Coll Cardiol,2014,63(17):1715-1723.

[5] Ha?ssaguerre M,Ja?s P,Shah DC,et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med,1998,339(10):659-666.

[6] Buist TJ,Zipes DP,Elvan A. Atrial fibrillation ablation strategies and technologies:past,present,and future[J]. Clin Res Cardiol,2021,110(6):775-788.

[7] Phlips T,Taghji P,El Haddad M,et al. Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation:the role of interlesion distance,ablation index,and contact force variability in the ‘CLOSE’-protocol[J]. Europace,2018,20(FI_3):f419-f427.

[8] Winkle RA,Mead RH,Engel G,et al. High-power,short-duration atrial fibrillation ablations using contact force sensing catheters:outcomes and predictors of success including posterior wall isolation[J]. Heart Rhythm,2020,17(8):1223-1231.

[9] Kuck KH,Albenque JP,Chun KJ,et al. Repeat ablation for atrial fibrillation recurrence post cryoballoon or radiofrequency ablation in the FIRE AND ICE trial[J]. Circ Arrhythm Electrophysiol,2019,12(6):e007247.

[10] Maurer T,Schlüter M,Kuck KH. Keeping it simple:balloon devices for atrial fibrillation ablation therapy[J]. JACC Clin Electrophysiol,2020,6(12):1577-1596.

[11] Dukkipati SR,Cuoco F,Kutinsky I,et al. Pulmonary vein isolation using the visually guided laser balloon:a prospective,multicenter,and randomized comparison to standard radiofrequency ablation[J]. J Am Coll Cardiol,2015,66(12):1350-1360.

[12] Schmidt B,Neuzil P,Luik A,et al. Laser balloon or wide-area circumferential irrigated radiofrequency ablation for persistent atrial fibrillation:a multicenter prospective randomized study[J]. Circ Arrhythm Electrophysiol,2017,10(12):e005767.

[13] Chun JKR,Bordignon S,Last J,et al. Cryoballoon versus laserballoon:insights from the first prospective randomized balloon trial in catheter ablation of atrial fibrillation[J]. Circ Arrhythm Electrophysiol,2021,14(2):e009294.

[14] Reddy VY,Neuzil P,Koruth JS,et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation[J]. J Am Coll Cardiol,2019,74(3):315-326.

[15] Bradley CJ,Haines DE. Pulsed field ablation for pulmonary vein isolation in the treatment of atrial fibrillation[J]. J Cardiovasc Electrophysiol,2020,31(8):2136-2147.

[16] Reddy VY,Dukkipati SR,Neuzil P,et al. Pulsed field ablation of paroxysmal atrial fibrillation:1-year outcomes of IMPULSE,PEFCAT,and PEFCAT Ⅱ[J]. JACC Clin Electrophysiol,2021,7(5):614-627.

[17] Koruth JS,Kuroki K,Iwasawa J,et al. Endocardial ventricular pulsed field ablation:a proof-of-concept preclinical evaluation[J]. Europace,2020,22(3):434-439.

[18] Schmidt B,Bordignon S,Tohoku S,et al. 5S Study:Safe and Simple Single Shot pulmonary vein isolation with pulsed field ablation using Sedation[J]. Circ Arrhythm Electrophysiol,2022,15(6):e010817.

[19] Wu G,Huang H,Cai L,et al. Long-term observation of catheter ablation vs. pharmacotherapy in the management of persistent and long-standing persistent atrial fibrillation (CAPA study)[J]. Europace ,2021,23(5):731-739.

[20] Mulder BA,Luermans JGLM,Hindricks G,et al. Innovations and paradigm shifts in atrial fibrillation ablation[J]. Europace,2021,23(23 suppl 2):ii23-ii27.

[21] Mulder MJ,Kemme MJB,Hopman LHGA,et al. Comparison of the predictive value of ten risk scores for outcomes of atrial fibrillation patients undergoing radiofrequency pulmonary vein isolation[J]. Int J Cardiol,2021,344:103-110.

[22] Kornej J,Hindricks G,Arya A,et al. The APPLE Score—A novel score for the prediction of rhythm outcomes after repeat catheter ablation of atrial fibrillation[J]. PLoS One,2017,12(1):e0169933.

[23] Kosiuk J,Dinov B,Kornej J,et al. Prospective,multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis:DR-FLASH score[J]. Heart Rhythm,2015,12(11):2207-2212.

[24] Seew?ster T,Büttner P,Zeynalova S,et al. Are the atrial natriuretic peptides a missing link predicting low-voltage areas in atrial fibrillation? Introducing the novel biomarker-based atrial fibrillation substrate prediction (ANP) score[J]. Clin Cardiol,2020,43(7):762-768.

[25] Marrouche NF,Wilber D,Hindricks G,et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation:the DECAAF study[J]. JAMA,2014,311(5):498-506.

[26] Khurshid S,Friedman S,Reeder C,et al. ECG-based deep learning and clinical risk factors to predict atrial fibrillation[J]. Circulation,2022,145(2):122-133.

[27] Willems S,Borof K,Brandes A,et al. Systematic,early rhythm control strategy for atrial fibrillation in patients with or without symptoms:the EAST-AFNET 4 trial[J]. Eur Heart J,2022,43(12):1219-1230.

[28] Calvert P,Lip GYH,Gupta D. Radiofrequency catheter ablation of atrial fibrillation:a review of techniques[J]. Trends Cardiovasc Med,2022,S1050-1738(22)00061-5.DOI: 10.1016/j.tcm.2022.04.002. Online ahead of print.

[29] Verma A,Jiang CY,Betts TR,et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med,2015,372(19):1812-1822.

[30] Wynn GJ,Panikker S,Morgan M,et al. Biatrial linear ablation in sustained nonpermanent AF:results of the substrate modification with ablation and antiarrhythmic drugs in nonpermanent atrial fibrillation (SMAN-PAF) trial[J]. Heart Rhythm,2016,13(2):399-406.

[31] Osmancik P,Herman D,Kacer P,et al. The efficacy and safety of hybrid ablations for atrial fibrillation[J]. JACC Clin Electrophysiol,2021,7(12):1519-1529.

[32] Valderrábano M,Peterson LE,Swarup V,et al. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation:the VENUS randomized clinical trial[J]. JAMA,2020,324(16):1620-1628.

[33] Hong KL,Borges J,Glover B. Catheter ablation for the management of atrial fibrillation:current technical perspectives[J]. Open Heart,2020,7(1):e001207.

[34] Kircher S,Arya A,Altmann D,et al. Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation:a randomized study[J]. Europace,2018,20(11):1766-1775.

[35] Bisbal F,Benito E,Teis A,et al. Magnetic resonance imaging-guided fibrosis ablation for the treatment of atrial fibrillation:the ALICIA trial[J]. Circ Arrhythm Electrophysiol,2020,13(11):e008707.

[36] Marrouche NF,Greene T,Dean JM,et al. Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation:the DECAAF Ⅱ trial :study design[J]. J Cardiovasc Electrophysiol,2021,32(4):916-924.

[37] Perry M,Kemmis Betty S,Downes N,et al. Atrial fibrillation:diagnosis and management-summary of NICE guidance[J]. BMJ,2021,373:n1150.

[38] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会. 经冷冻球囊导管消融心房颤动中国专家共识[J] . 中华心律失常学杂志,2020,24 (2):96-112.

[39] Kaitani K,Inoue K,Kobori A,et al. Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial[J]. Eur Heart J,2016,37(7):610-618.

[40] Duytschaever M,Demolder A,Phlips T,et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF):results from a multicentre randomized trial[J]. Eur Heart J,2018,39(16):1429-1437.

[41] Zhang M,Ren Y,Wang L,et al. Cost-effectiveness of dronedarone and amiodarone for the treatment of Chinese patients with atrial fibrillation[J]. Front Public Health,2021,9:726294.

[42] Naccarelli GV,Bhatt DL,Camm AJ,et al. Evaluation of the switch from amiodarone to dronedarone in patients with atrial fibrillation:results of the ARTEMIS AF studies[J]. J Cardiovasc Pharmacol Ther,2020,25(5):425-437.

[43] Chen HS,Wen JM,Wu SN,et al. Catheter ablation for paroxysmal and persistent atrial

fibrillation[J]. Cochrane Database Syst Rev,2012,(4):CD007101.

[44]Phillips KP,Walker DT,Humphries JA. Combined catheter ablation for atrial fibrillation and

Watchman? left atrial appendage occlusion procedures:five-year experience[J]. J Arrhythm. 2016,32(2):119-126.

[45] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the Management of Atrial

Fibrillation Developed in Collaboration With EACTS[J]. Rev Esp Cardiol (Engl Ed),2017,70(1):50.

[46] Packer DL,Mark DB,Robb RA,et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality,stroke,bleeding,and cardiac arrest among patients with atrial fibrillation:the CABANA randomized clinical trial[J]. JAMA,2019,321(13):1261-1274.

[47] Packer DL,Piccini JP,Monahan KH,et al. Ablation versus drug therapy for atrial fibrillation in heart failure:results from the CABANA trial[J]. Circulation,2021,143(14):1377-1390.

[48] Bahnson TD,Giczewska A,Mark DB,et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation:results from the CABANA trial[J]. Circulation,2022,145(11):796-804.

[49] Brachmann J,Sohns C,Andresen D,et al. Atrial fibrillation burden and clinical outcomes in heart? Failure:the CASTLE-AF trial[J]. JACC Clin Electrophysiol,2021,7(5):594-603.

[50] Kirchhof P,Camm AJ,Goette A,et al. Early rhythm-control therapy in patients with atrial fibrillation[J]. N Engl J Med,2020,383(14):1305-1316.

相似文献/References:

[1]马正科 何智余 姚亚丽.心房颤动脉冲电场消融的研究进展[J].心血管病学进展,2021,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
　MA Zhengke,HE Zhiyu,YAO Yali.Pulsed Field Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
[2]王学文?柯元甲?赵庆彦.自主神经调控免疫重构与房颤的发生[J].心血管病学进展,2023,(7):645.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.016]
　WANG Xuewen,KE Yuanjia,ZHAO Qingyan.Autonomic Nerve Regulates Immune Remodeling and The Occurrence of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(6):645.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.016]

更新日期/Last Update: 2023-07-20